MRK
Merck & Co., Inc.
MRK's outlook is improving despite an expensive valuation.
OSCR
Oscar Health, Inc.
OSCR has the edge over MRK overall, supported by stronger modeled upside and stronger valuation.
MRK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
MRK's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MRK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $14.38 | -90% |
| Forward | 17x | $147 | — |
| Fair | 21x | $20.03 | -86% |
| Expensive | 58x | $55.80 | -62% |
| Current | 151x | $147 | — |
Historical ranges are pointers, not guarantees.
MRK's PE is in its expensive range at 151x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over MRK in the historical PE scenario, which offers more potential upside but is not a forecast.
MRK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect MRK's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MRK on the outlook, with more favorable revenue expectations.
MRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.42 | +768% |
| Q3 2026 | $0.97 | -87% |
| Q2 2026 | $1.25 | -81% |
| Q1 2026 | $3.55 | -48% |
| Q4 2025 | $7.28 | +8% |
| Q3 2025 | $7.58 | +59% |
| Q2 2025 | $6.50 | +21% |
| Q1 2025 | $6.88 | +664% |
| Q4 2024 | $6.74 | +4714% |
MRK has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.1B | +4.7% |
| Q2 2026 | $16.6B | +5.1% |
| Q1 2026 | $16.3B | +4.9% |
| Q4 2025 | $16.4B | +5% |
| Q3 2025 | $17.3B | +3.7% |
| Q2 2025 | $15.8B | -1.9% |
| Q1 2025 | $15.5B | -1.6% |
| Q4 2024 | $15.6B | +6.8% |
MRK's revenue has grown year over year for five quarters in a row: $18.1B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | -8.3 points |
| Q2 2026 | -4.1% | -36 points |
| Q1 2026 | -22% | -60 points |
| Q4 2025 | 21% | -5.8 points |
| Q3 2025 | 39% | +15 points |
| Q2 2025 | 32% | -5.7 points |
| Q1 2025 | 38% | +2.1 points |
| Q4 2024 | 27% | +41 points |
MRK has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MRK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.5B | -19% |
| Q2 2026 | $4.5B | +77% |
| Q1 2026 | $2.9B | +150% |
| Q4 2025 | $1.8B | -27% |
| Q3 2025 | $6.8B | -20% |
| Q2 2025 | $2.5B | -48% |
| Q1 2025 | $1.2B | -47% |
| Q4 2024 | $2.5B | +$3.3B |
MRK generated $14.7B in free cash flow over the past year, up 13% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MRK on cash flow, with more consistent year-over-year improvement.
MRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +8M shares |
| 1 year | -0.8% | -20M shares |
| 3 years | -2.7% | -68M shares |
| 5 years | -2.3% | -58M shares |
| Available history | -8.4% | -226M shares |
MRK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $653M |
| Q2 2026 | $757M |
| Q1 2026 | $874M |
| Q4 2025 | $1.3B |
| Q3 2025 | $1.3B |
| Q2 2025 | $1.3B |
| Q1 2025 | $1.2B |
| Q4 2024 | $489M |
MRK spent $3.5B buying back its own shares over the past year, down 18% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MRK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 5.1x | High |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
MRK's net debt is about 5.4 years of its operating earnings (EBITDA), up from a year a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MRK on leverage, with a lower net debt burden relative to earnings.
MRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.5 | Neutral |
| Stochastic | 69.3 | Neutral |
MRK's weekly RSI is 61 (neutral) and its Stochastic is 69 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MRK PE vs Healthcare Sector
| Metric | MRK | Sector median | Relative |
|---|---|---|---|
| PE | 151x | 26x | 486% above |
| PE % | 98 | 29 | 69 pts above |
MRK is trading at 151x earnings, a 486% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MRK on valuation relative to its sector.
MRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $146.6 | 0.2% above |
| 20 week MA | $141.1 | 4.2% above |
| 50 week MA | $125.2 | 17% above |
| 100 week MA | $105.9 | 39% above |
| 200 week MA | $109.8 | 34% above |
MRK has climbed back above all five of its weekly moving averages, and it's now 34% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.3 | $76.4 | -12% |
| 2021 | $76.4 | $75.7 | -0.9% |
| 2022 | $75.7 | $111.9 | +48% |
| 2023 | $111.9 | $109.0 | -2.5% |
| 2024 | $109.0 | $99.7 | -8.5% |
| 2025 | $99.7 | $106.8 | +7.1% |
| 2026 YTD | $106.8 | $147.0 | +38% |
MRK is up 38% so far in 2026, after finishing lower in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MRK on returns for 2026, with the stronger performance.